We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
8.00 | 0.47% | 1,713.00 | 1,713.00 | 1,713.50 | 1,714.50 | 1,695.50 | 1,705.00 | 1,214,079 | 13:37:31 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.30 | 70.48B |
TIDMGSK
RNS Number : 4344F
GlaxoSmithKline PLC
12 July 2019
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Ms E Walmsley === ======================== ============================================ b) Position/status Chief Executive Officer === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP16.5060 19 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2019-07-11 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mr R G Connor === ======================== ============================================ b) Position/status President, Global Vaccines === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP16.5060 62 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2019-07-11 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mr N Hirons === ======================== ============================================ b) Position/status SVP, Global Ethics & Compliance === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP16.5060 12 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2019-07-11 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mrs S Jackson === ======================== ============================================ b) Position/status SVP, Global Communications and CEO Office === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 11 July 2019, on shares
held through the Company's Share Reward Plan. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP16.5060 57 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2019-07-11 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ========================================================================== a) Name Mr D Jackson === ======================== ================================================ b) Position/status PCA of Mrs S Jackson (SVP, Global Communications and CEO Office) === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP16.5060 19 ---------- === ======================== ================================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ================================================ e) Date of the transaction 2019-07-11 === ======================== ================================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mr L Miels === ======================== ============================================ b) Position/status President, Global Pharmaceuticals === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP16.5060 3 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2019-07-11 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mr D S Redfern === ======================== ============================================ b) Position/status Chief Strategy Officer === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP16.5060 70 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2019-07-11 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mr R Simard === ======================== ============================================ b) Position/status President, Pharmaceuticals Supply Chain === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================
b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP16.5060 19 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2019-07-11 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mr P C Thomson === ======================== ============================================ b) Position/status President, Global Affairs === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP16.5060 40 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2019-07-11 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mrs V A Whyte === ======================== ============================================ b) Position/status Company Secretary === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP16.5060 51 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2019-07-11 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHZLLFFKDFEBBF
(END) Dow Jones Newswires
July 12, 2019 10:55 ET (14:55 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions